Orexigen Therapeutics (OTCMKTS:OREXQ) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.
Risk & Volatility
Orexigen Therapeutics has a beta of 4.98, indicating that its stock price is 398% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.
Profitability
This table compares Orexigen Therapeutics and Capricor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orexigen Therapeutics | N/A | N/A | N/A |
| Capricor Therapeutics | -660.66% | -264.61% | -114.31% |
Institutional & Insider Ownership
4.3% of Capricor Therapeutics shares are owned by institutional investors. 13.3% of Orexigen Therapeutics shares are owned by company insiders. Comparatively, 16.3% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Orexigen Therapeutics and Capricor Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orexigen Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Capricor Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Capricor Therapeutics has a consensus target price of $19.50, indicating a potential upside of 1,014.29%. Given Capricor Therapeutics’ higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Orexigen Therapeutics.
Valuation & Earnings
This table compares Orexigen Therapeutics and Capricor Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orexigen Therapeutics | $33.71 million | 0.00 | -$24.52 million | N/A | N/A |
| Capricor Therapeutics | $1.67 million | 4.45 | -$15.19 million | ($5.20) | -0.34 |
Capricor Therapeutics has lower revenue, but higher earnings than Orexigen Therapeutics.
Summary
Capricor Therapeutics beats Orexigen Therapeutics on 6 of the 11 factors compared between the two stocks.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Receive News & Ratings for Orexigen Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Orexigen Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
